Biogen Idec Deal Uses GSK Model; Partnerships To Double Pipeline By 2010
Executive Summary
Biogen and Idec are applying the GlaxoSmithKline model to the biotech world with their $6.8 bil. merger agreement
You may also be interested in...
The Architect Of Biogen's Controversial Alzheimer's Strategy, Al Sandrock, To Retire
Despite 23 years at Biogen assisting in the development of several drugs, Sandrock's legacy will be tied to Alzheimer’s drug Aduhelm.
Biogen Idec Highlights Manufacturing Capacity To Attract Partnerships
Biogen Idec plans to focus on licensing deals rather than mergers to grow its pipeline going forward, Executive VP-Business Development Mark Wiggins said during the company's analyst day Nov. 30
Biogen Idec Highlights Manufacturing Capacity To Attract Partnerships
Biogen Idec plans to focus on licensing deals rather than mergers to grow its pipeline going forward, Executive VP-Business Development Mark Wiggins said during the company's analyst day Nov. 30